close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

147.34 +3.90 (+2.72%)
Streaming Delayed Price Updated: 10:57 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health ↗
Via Chartmill
News headline image
Compugen Q1 Earnings Call Highlights ↗
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company... 
Via MarketBeat
Topics Earnings
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance ↗
Via Chartmill
News headline image
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline ↗
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and... 
Via MarketBeat
News headline image
3 Market-Beating Stocks to Research Further
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
News headline image
Gilead Prices $3 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing... 
Via MarketBeat
News headline image
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and d... 
Via StockStory
Topics Earnings
News headline image
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead (GILD) Q1 2026 Earnings Call Transcript ↗
Gilead (GILD) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to... 
Via StockStory
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year... 
Via StockStory
News headline image
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy ↗
Gilead Sciences issued a mixed guidance update late Thursday after the biotech company beat first-quarter sales expectations. 
Via Investor's Business Daily
News headline image
Gilead Sciences Announces First Quarter Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS and $6.92B revenue. Stock closed at $136.30 on April 29. 
Via Benzinga
News headline image
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗
Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Thursday after market close. Here’s what you need to know. Gilead Sci... 
Via StockStory
Topics Artificial Intelligence
News headline image
Tempus AI (TEM) Q1 2026 Earnings Transcript ↗
Tempus AI (TEM) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 S&P 500 Stock to Own for Decades and 2 We Avoid
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
News headline image
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?
Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗
This fixed-income ETF offers diversified bond exposure and a flexible strategy focused on income and sector allocation. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.